Revenue growth in every region, record-high sales for a consecutive period, and increased market share

「As a result, revenue for the interim consolidated period increased 1.4% year on year, continuing the growth recorded in the previous year. In peripheral markets, surgical wear performed steadily, up 6.4% year on year, while patient wear declined 9.3% because acquiring new projects was difficult. As a result, total peripheral-market revenue declined 4.0% year on year. In contrast, overseas revenue increased sharply by 35.0% year on year, helped by projects carried over from the previous fiscal year in Taiwan and the opening of the Seoul branch.」

「In peripheral markets, revenue increased 5.7%, as patient wear steadily shifted toward high-value-added products and the acquisition of new surgical wear projects progressed. In overseas markets, revenue declined 15.1%, significantly affected by delays in bidding for projects scheduled for the fourth quarter, given the small scale of the business.」

「In the core market, projects carried over from the previous fiscal year were renewed successively, mainly for high-function products, and deliveries of planned large projects progressed steadily. The high-end MACKINTOSH PHILOSOPHY product, launched in the previous fiscal year, also performed well, resulting in revenue growth of 6.6% year on year. In peripheral markets, sales of high-value-added patient wear, where demand is expanding, increased, and the surgical market also performed steadily through the acquisition of new projects, resulting in growth of 6.4%, broadly in line with the plan. In contrast, overseas revenue declined sharply by 23.5%, as planned large projects were shifted to the fourth quarter and the business is small in scale.」

「The Group's (the Company and its consolidated subsidiaries') sales for the consolidated fiscal year declined 4.5% year on year, a difficult result.」

「Although market conditions remain unstable, we will focus on revenue growth in the core market and work to achieve our targets in the fourth-quarter consolidated period.」

「In the core market, projects carried over from the previous fiscal year were caught up, but challenging market conditions persisted. As in the previous fiscal year, delays in product selection and price negotiations caused some renewal projects to shift between months, resulting in an 8.6% year-on-year decline. Patient wear in peripheral markets also declined due to reduced material purchases by linen suppliers responding to higher costs. In contrast, the overseas market performed steadily, with revenue up 11.3% year on year, partly because revenue had declined in the previous fiscal year.」

「In the core market, orders for core healthcare wear progressed, centered on renewal projects carried over from the previous fiscal year. However, continued challenging market conditions led to new projects being shifted between months, resulting in revenue growth of 2.1%. The peripheral markets performed steadily, with revenue up 6.9%, driven by market share gains in patient wear. In contrast, overseas revenue declined 17.9%, reflecting the significant impact of fluctuations in project volume given the small scale of the business.」

「For revenue, we aim to achieve record-high sales of ¥17,800 million, up 3.6% year on year.」

「In the fourth quarter, we will reliably catch up on projects whose renewals have been delayed and work to recover revenue.」

「Sales by the Group, comprising the Company and its consolidated subsidiaries, for the cumulative second-quarter consolidated period increased 1.5% year on year to ¥7,931 million.」

「Overall, we plan to increase revenue in all markets and aim to achieve record-high sales for the fourth consecutive period, up 2.6% year on year.」

「Excluding the special factors of one-off sales to the Ministry of Health, Labour and Welfare in the previous fiscal year and the change in accounting standards for revenue recognition, revenue declined 0.4% year on year, remaining approximately at the previous year's level.」

「Revenue in the prior-year period rose sharply by 14.4%, reflecting deliveries of projects carried over as a result of the COVID-19 pandemic, the acquisition of large new projects, COVID-related special demand and one-off sales to the Ministry of Health, Labour and Welfare. Although a significant decline from that elevated prior-year level had been anticipated, the company focused on securing orders for scheduled renewal projects and acquiring new projects in the core market, expanding sales of strong-performing patient wear in peripheral markets, and winning a large project in Taiwan in overseas markets. As a result, the decline was limited to 3.1% year on year. Excluding the one-off sales to the Ministry of Health, Labour and Welfare and the special factors related to the adoption of accounting standards for revenue recognition in the previous fiscal year, revenue increased 1.2% year on year.」

「The prior-year period was significantly affected by the one-off ¥315 million delivery of infection-control products to the Ministry of Health, Labour and Welfare. Excluding this special-factor revenue, revenue increased by ¥97 million, or 3.0%. Most product categories, including healthcare wear in the core market and patient wear in peripheral markets, continued to perform steadily as planned.」

「Under these circumstances, the Group will launch new products based on new concepts in the core healthcare wear and doctor wear markets, stimulating the markets while securing orders for renewal projects and pursuing market share gains. In addition, the Group will seek revenue growth in peripheral markets through patient wear, where substantial growth is expected to continue, and surgical wear, where market penetration of Compel Pack is expected. This will offset the loss of sales delivered to the Ministry of Health, Labour and Welfare, and the Group aims to achieve record-high sales, up 0.8% year on year.」

「As a result, revenue for the cumulative nine-month consolidated period increased sharply by 14.2% year on year, reaching a record high for the period.」

「As a result, revenue for the cumulative second-quarter consolidated period increased across all product categories and domestic regions, rising sharply by 14.4% year on year and reaching a record high for the period.」

「Core healthcare wear and doctor wear recorded substantial sales growth as renewal contracts postponed from the previous fiscal year were steadily brought back on schedule. Patient wear also began to gain traction as new initiatives that had lagged the previous fiscal year got underway, while surgical wear continued to perform well, particularly ComPel Pack. As a result, sales in the surrounding markets grew by more than double digits. Infection-control products developed and launched in the previous fiscal year also made a significant contribution to sales, including through large deliveries to the Ministry of Health, Labour and Welfare. Consequently, sales for the cumulative first quarter reached a record high, up 24.6% year on year.」

「We expect deliveries to proceed successively, including for projects carried over from the previous fiscal year. Together with continued growth in demand for surgical wear and steady revenue growth in patient wear, where initiatives began late in the previous fiscal year, we aim to achieve record-high sales, up 1.4% year on year.」

「As a result, although infection-control products performed well, they could not fully offset the decline in the core product range, and revenue for the cumulative nine-month consolidated period declined 4.9%.」

「Affected by the COVID-19 pandemic, deliveries, mainly of core healthcare wear, were delayed. As a result of a sharp decline in February alone, revenue for the cumulative second-quarter period declined 2.5% year on year.」

「Against this backdrop, the Group (the Company and its consolidated subsidiaries) recorded a slight 0.8% year-on-year decline in sales for the cumulative first quarter, as solid markets surrounding surgical wear and patient wear were offset by some impact from market disruption on its core healthcare wear business.」

「Despite these circumstances, the Group will continue strengthening the high-value-added strategy developed over the past several years to meet customer needs and convert renewal projects, including those carried over from the previous fiscal year, into firm orders in the healthcare wear business. Together with revenue growth from new patient wear accounts, the Group aims to achieve record-high sales.」

「Renewal projects were originally concentrated in the fourth quarter, and new initiatives in patient wear have also been decided. Although some renewal projects have been delayed into the next fiscal year, full-year revenue is expected to recover to approximately the previous year's level.」

「Although the second quarter was on a recovery trend compared with the first quarter, there were few facilities scheduled for renewal in the core healthcare-wear business, and the same period of the previous year had recorded substantial growth of 3.8%. As a result, revenue for the cumulative second quarter of the consolidated fiscal year declined 2.5% year on year.」

「The company achieved record-high sales for the current consolidated fiscal year, continuing its consecutive record-setting performance.」

「Revenue for the cumulative nine-month period of the current consolidated fiscal year reached a record high.」

「Under its high-value-added product strategy, the Group, comprising the Company and its consolidated subsidiaries, exceeded its sales plan and achieved record-high sales. This followed steady revenue growth in the core healthcare-wear business and continued strong performance from patient wear, which posted double-digit growth for the second consecutive period.」

「In addition to steady revenue growth in the core healthcare wear business, patient wear continued to perform well, and a range of highly functional, highly appealing, high-value-added new products drove overall performance. As a result, we exceeded our plan and achieved record-high sales for consecutive periods.」

「Against this backdrop, the Group, comprising the Company and its consolidated subsidiaries, achieved record-high revenue for the cumulative third quarter of the consolidated fiscal year. Healthcare wear and surgical wear performed steadily, while patient wear recorded substantial revenue growth.」

「Under its high-value-added product strategy, the Group, comprising the Company and its consolidated subsidiaries, secured orders for renewals of its core healthcare-wear products and won new facilities, while patient wear performed well. As a result, revenue increased 3.0% year on year, the sales plan was exceeded, and record-high sales were achieved.」

「By launching new high-value-added products offering advanced functionality and strong appeal in each market, we aim to stimulate the markets and increase market share. We plan to increase revenue in every region and achieve record-high sales for consecutive periods.」